Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in AAV
NCT04973033Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofacitinib oral solution in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Response Rate (Complete, Partial, and Treatment Response) at 13 months. Started Dec 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT04973033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973033.